Dinesh Ph D Patel V sold $18M of PTGX
President and CEO at Protagonist Therapeutics, Inc. 125,000 shares at an average of $145.92, traded Sep 8, 2026, filed Sep 10, 2026.
Score components
- +25RoleCEO
- +25Trade size$18.2M at market
- +5Share of holdings soldSold 22% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-106831, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | MOption exercise Common Stock10b5-1 | +54,174 | $21.58 | $1.2M | 577,142 | 34 d ago |
| Sep 8, 2026 | SOpen-market sale Common Stock10b5-1 | -54,174 | $145.87 | $7.9M | 522,968 | 34 d ago |
| Sep 9, 2026 | MOption exercise Common Stock10b5-1 | +63,548 | $21.58 | $1.4M | 586,516 | 34 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -63,548 | $146.18 | $9.3M | 522,968 | 34 d ago |
| Sep 10, 2026 | MOption exercise Common Stock10b5-1 | +7,278 | $21.58 | $157k | 530,246 | 34 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stock10b5-1 | -7,278 | $144.10 | $1.0M | 522,968 | 34 d ago |
| Sep 8, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -54,174 | $0.00 | $0 | 70,826 | 34 d ago |
| Sep 9, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -63,548 | $0.00 | $0 | 7,278 | 34 d ago |
| Sep 10, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,278 | $0.00 | $0 | 0 | 34 d ago |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $8.3M 58,629 shares | -50% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $15M 100,000 shares | -17% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $1.1M 9,000 shares | -53% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $969k 9,000 shares | -53% | |
| 24Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $897k 9,000 shares | -53% | |
| 28Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $7.5M 75,000 shares | -13% | |
| 48Moderate | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $7.5M 75,000 shares | -13% | |
| 53Moderate | Protagonist Therapeutics, Inc | Bryan Giraudo director | $5.9M 59,130 shares | -93% | |
| 34Weak | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $185k 1,750 shares | -3% | |
| 57Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $2.6M 24,765 shares | -29% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.